What does this TikTok actually claim?
The video focuses on Victoza (liraglutide) for weight loss, using hashtags that suggest the creator is documenting their injection experience. Without access to the specific claims made in the video content, we can address what viewers typically encounter in Victoza weight loss content.
Most TikTok posts about Victoza discuss injection techniques, side effects, or weight loss results. The hashtags suggest this falls into the personal experience category that's become common on the platform.
What does the science actually say about Victoza?
Victoza contains liraglutide, a GLP-1 receptor agonist originally approved for type 2 diabetes. The SCALE Obesity and Prediabetes trial (Pi-Sunyer et al., NEJM, 2015) tested 3.0mg daily liraglutide specifically for weight management.
That study found 8.0% average weight loss at 56 weeks compared to 2.6% with placebo. About 63% of participants lost at least 5% of their body weight. The FDA approved this higher dose as Saxenda, not Victoza, for weight management.
Here's where it gets confusing: Victoza is approved at lower doses (up to 1.8mg daily) for diabetes, not weight loss. Many people use these terms interchangeably, but they're technically different products.
What are people getting wrong about liraglutide?
The biggest misconception is that Victoza and Saxenda are identical. They contain the same drug but at different approved doses for different conditions. Using Victoza off-label for weight loss means you're getting a lower dose than what was studied for obesity.
Many TikTok creators also skip over the significant side effects. In the SCALE trial, 48% of liraglutide users had gastrointestinal side effects versus 28% on placebo. About 9% stopped treatment due to side effects.
The injection technique content can be helpful, but medical supervision matters more than perfect injection form when you're dealing with nausea, vomiting, or other adverse effects.
How does this compare to newer options?
Liraglutide was the first-generation GLP-1 for weight loss, but newer options show better results. The STEP 1 trial (Wilding et al., NEJM, 2021) found 14.9% weight loss with semaglutide 2.4mg (Wegovy) versus 2.4% with placebo.
Tirzepatide (Zepbound) performed even better in the SURMOUNT-1 trial (Jastreboff et al., NEJM, 2022), with 20.9% average weight loss at the highest dose. Both require weekly injections instead of daily like liraglutide.
That doesn't make liraglutide worthless, but it explains why many providers now prescribe the newer agents first. The daily injections alone make liraglutide less convenient.
What should you actually know?
Liraglutide works through legitimate mechanisms: it slows gastric emptying, reduces appetite, and affects brain regions that control food intake. The weight loss is real, just more modest than newer alternatives.
If you're considering any GLP-1 medication, the specific drug matters less than proper medical supervision. These medications can affect blood sugar even in non-diabetics and interact with other conditions.
TikTok experiences can be informative, but they shouldn't replace discussions with healthcare providers who know your medical history. Individual results vary significantly, and what works for one creator might not work for you.